Using APP23 transgenic mice as a model of amyloid pathology in AD, Katsouri et al. (2015) found that exogenous bFGF administration improved Tau pathology and spatial memory impairment by downregulating BACE1 [121]. This evidence concerns the gene FGF2 and Alzheimer disease.